Evidence map›Paper›PMID 30928964›Full record

ArticleBMJ open2019

Trends in hepatitis C treatment initiation among HIV/hepatitis C virus-coinfected men engaged in primary care in a multisite community health centre in Maryland: a retrospective cohort study.

Yun-Chi Chen, Chloe L Thio, Andrea L Cox, Sebastian Ruhs, Farin Kamangar, Kjell J Wiberg

Abstract read
In one paragraph

Article in BMJ open, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yun-Chi ChenDepartment of Biology, Morgan State University, Baltimore, Maryland, USA.ORCID 0000-0003-2787-1247
Chloe L ThioDepartment of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
Andrea L CoxDepartment of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
Sebastian RuhsChase Brexton Health Care, Baltimore, Maryland, USA.
Farin KamangarDepartment of Biology, Morgan State University, Baltimore, Maryland, USA.
Kjell J WibergDepartment of Medicine, Sinai Hospital, Baltimore, Maryland, USA.

Funding

Project-002UL1GM118973 · NIGMS · MORGAN STATE UNIVERSITY · PI KAMANGAR, FARIN · 2015 to 2023
$18.8M
NIGMS NIH HHS UL1 GM118973
6 · The paper itself

Abstract

objectivesLittle is known about the cascade of hepatitis C care among HIV/hepatitis C virus (HCV)-coinfected patients in community-based clinics. Thus, we analysed our data from the interferon era to understand the barriers to HCV treatment, which may help improve getting patients into treatment in the direct-acting antivirals era.

designRetrospective cohort study.

settingFour HIV clinics of a multisite community health centre in the USA.

participants1935 HIV-infected men with >1 medical visit to the clinic between 2011 and 2013. Of them, 371 had chronic HCV and were included in the analysis for HCV care continuum during 2003-2014. OUTCOME MEASURES: HCV treatment initiation was designated as the primary outcome for analysis. Multivariate logistic regression was performed to identify factors associated with HCV treatment initiation.

resultsAmong the 371 coinfected men, 57 (15%) initiated HCV treatment. Entering care before 2008 (adjusted OR [aOR, 3.89; 95% CI, 1.95 to 7.78), higher educational attainment (aOR, 3.20; 95% CI, 1.59 to 6.44), HCV genotype 1 versus non-1 (aOR, 0.21; 95% CI, 0.07 to 0.65) and HIV suppression (aOR, 2.13; 95% CI, 1.12 to 4.06) independently predicted treatment initiation. Stratification by entering care before or after 2008 demonstrated that higher educational attainment was the only factor independently associated with treatment uptake in both periods (aOR, 2.79; 95% CI, 1.13 to 6.88 and aOR, 4.10; 95% CI, 1.34 to 12.50, pre- and post-2008, respectively). Additional associated factors in those entering before 2008 included HCV genotype 1 versus non-1 (aOR, 0.09; 95% CI, 0.01 to 0.54) and HIV suppression (aOR, 2.35; 95% CI, 1.04 to 5.33).

conclusionsSome traditional barriers predicted HCV treatment initiation in those in care before 2008; however, the patients' level of educational attainment remained an important factor even towards the end of the interferon era. Further studies will need to determine whether educational attainment persists as an important determinant for initiating direct-acting antiviral therapies.

Indexed as

AdultAntiviral AgentsHepatitis CHIV InfectionsHumansLogistic ModelsMaleMarylandMiddle AgedMultivariate AnalysisPrimary Health CareRetrospective StudiesAntiviral Agentscare continuumeducational attainmentHCV treatmentHIVHIV/HCV coinfection

Identifiers

PMID30928964
PMCPMC6475218

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.